Multiple Myeloma Pricing, Reimbursement, and Access

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2eg9INj on October 31, 2016 at 02:52PM

This report addresses the following questions:

  • How do access restrictions for multiple myeloma drugs differ across markets and why?
  • Which clinical trial comparators and outcomes are necessary for approval and uptake in each market?
  • What impact, if any, will value assessment tools have on US reimbursement patterns?
  • When and where are risk-sharing agreements useful in gaining market access?
  • What are US and EU payers’ and physicians’ opinions on monoclonal antibodies Darzalex and Empliciti?
  • What effect will generic bortezomib have on the pricing and reimbursement of multiple myeloma drugs in the US and EU markets?

 

Find more information and order your copy here. (Source: ResearchandMarkets, May 2016)